Day: November 1, 2022

On November 28, 2017, Lu, Hualong published a patent.Electric Literature of 97859-49-9 The title of the patent was Preparation of oxazolidinone compounds as antibiotic agents. And the patent contained the following:

The title compounds shown in general formula I [wherein, R1 is selected from the groups as 3-amino-pyrrolidin-1-yl, N-methyl-3-amino-piperidin-1-yl, (R)-3-aminohexahydroazepin-1-yl, N-methyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, pyrrol-1-yl, 3-methylpyrrol-1-yl, etc.; R2 is selected from H, hydroxy, Me, halogen, etc.; R3 is selected form OH, NHCOCH3, etc.] or pharmaceutically acceptable salts or isomers thereof were prepared as antibiotic agents. For example, compound II was prepared in a multi-step synthesis. The inventive compound can be applied in preparing the drugs for treating microbial infection, and II showed antibacterial activities against both Staphylococcus aureus and Staphylococcus epidermidis with MIC values of 0.25 μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Electric Literature of 97859-49-9

The Article related to preparation oxazolidinone antibiotic agent treatment human bacterial infection, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On July 3, 2014, Yang, Yushe; Guo, Bin; Li, Zhan; Li, Wei published a patent.Synthetic Route of 97859-49-9 The title of the patent was Benzoxazine-oxazolidinone compounds as antiinfective agents and their preparation, pharmaceutical compositions and use in the treatment of multidrug resistant bacterial infections. And the patent contained the following:

Disclosed are benzoxazine-oxazolidinone compounds of formula I and their optical isomers, pharmaceutically acceptable salts, preparation method and application in preparing drugs for treating an infectious disease and in particular, an infectious disease caused by multidrug resistant bacteria. Compounds of formula I wherein R1 is amino and derivatives, phosphonate, succinate, L-arginine; R2 is (un)branched alkyl; R3 is halo, CN, OH, amino and derivatives, etc.; and their optical isomers, pharmaceutically acceptable salts thereof, are claimed. Compounds of formula I were prepared by using cross-coupling as the key steps. All the invention compounds were evaluated for their antibacterial activity. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Synthetic Route of 97859-49-9

The Article related to benzoxazine oxazolidinone preparation antiinfective treatment multidrug resistant bacterial infection, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On January 4, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.SDS of cas: 97859-49-9 The title of the patent was Preparation of anti-bacterial heterocyclic compounds. And the patent contained the following:

The title compounds I [R1 = alkyl, cycloalkyl, alkylamino, etc.; R2 = H, F, Cl, etc.; R3 = H, alkyl, F, etc.; X1 = N or CR4 (wherein R4 = H, halo, cyano, etc.); X2 = N or CR5 (R5 = H, halo, cyano, etc.); X3 = N or CR6; and X4 = CR6 when dotted line represents a bond (R6 = H, cyano, alkyl, etc.); or X3 = CH2 or O; and X4 = CH2 when dotted line represents no bond; n = 0-2; Y1 and Y2 = (independently) N or CR7 (R7 = H, halo, cyano, etc.); Z1 = O, S, NH, CH2; R8 = H, OH, alkyl, F] along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof, useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa, were prepared E.g., a multi-step synthesis of (S)-II, starting 6-methoxy-1,5-naphthyridin-4-ol and chloro(chloromethyl)dimethylsilane, was described. Exemplified compounds I were tested for their antibacterial activity (data given). Pharmaceutical compositions comprising compound I, alone and in combination with at least one antibiotic, were disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).SDS of cas: 97859-49-9

The Article related to heterocyclic compound pyridooxazinone pyrazinooxazinone preparation antibacterial antiviral antifungal protozoacide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On June 6, 2019, Mohamed, Shahul Hameed Peer; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Product Details of 97859-49-9 The title of the patent was Preparation of anti-bacterial heterocyclic compounds. And the patent contained the following:

The title compounds I [R1 = alkyl, cycloalkyl, alkylamino, etc.; R2 = H, F, Cl, etc.; R3 = H, alkyl, F, etc.; X1 = N or CR4 (wherein R4 = H, halo, cyano, etc.); X2 = N or CR5 (R5 = H, halo, cyano, etc.); X3 = N or CR6; and X4 = CR6 when dotted line represents a bond (R6 = H, cyano, alkyl, etc.); or X3 = CH2 or O; and X4 = CH2 when dotted line represents no bond; n = 0-2; Y1 and Y2 = (independently) N or CR7 (R7 = H, halo, cyano, etc.); Z1 = O, S, NH, CH2; R8 = H, OH, alkyl, F] along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof, useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa, were prepared E.g., a multi-step synthesis of (S)-II, starting 6-methoxy-1,5-naphthyridin-4-ol and chloro(chloromethyl)dimethylsilane, was described. Exemplified compounds I were tested for their antibacterial activity (data given). Pharmaceutical compositions comprising compound I, alone and in combination with at least one antibiotic, were disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to heterocyclic compound pyridooxazinone pyrazinooxazinone preparation antibacterial antiviral antifungal protozoacide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 12, 2009, Davies, Stephen G.; Elend, Dirk L.; Jones, Simon; Roberts, Paul M.; Savory, Edward D.; Smith, Andrew D.; Thomson, James E. published an article.Electric Literature of 168297-86-7 The title of the article was The dienolate aldol reaction of (E)-N-crotonoyl C(4)-isopropyl SuperQuat: asymmetric synthesis of α-vinyl-β-hydroxy carboxylic acid derivatives and conversion to α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products). And the article contained the following:

The synthesis of α-vinyl-β-hydroxy esters and α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products) via the dienolate aldol reaction of (E)-N-crotonoyl C(4)-iso-Pr SuperQuat is described. High levels of syn-diastereoselectivity (up to >98% de) are observed for the dienolate aldol reaction with boron enolates, generated either directly with Bu2BOTf or by transmetalation of the potassium enolate with B-bromocatecholborane. Cleavage of the resultant syn-aldol products from the auxiliary gives α-vinyl-β-hydroxy esters in >98% de and >98% ee. Subsequent isomerization of the double bond into conjugation provides α-ethylidene-β-hydroxy esters (β-substituted Baylis-Hillman products) in high diastereo- and enantiopurity (≥91:9 [(E):(Z)] and >98% ee). The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Electric Literature of 168297-86-7

The Article related to hydroxy ester vinyl ethylidene stereoselective preparation aldol crotonoyloxazolidinone, Aliphatic Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.Electric Literature of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 22, 2010, Hiebel, Marie-Aude; Pelotier, Beatrice; Piva, Olivier published an article.Computed Properties of 168297-86-7 The title of the article was Stereoselective synthesis of the C1-C13 fragment of bistramide A. And the article contained the following:

The C1-C13 fragment I of bistramide A was prepared from 5-hexenoic acid in 15 linear steps and in 16% overall yield. The core 2,6-trans-tetrahydropyran ring was obtained via a kinetically controlled oxa-Michael cyclization from the corresponding chiral α,β-unsaturated hydroxyester. This precursor was prepared by using a diastereoselective alkylation reaction using Davies Superquat auxiliary and a diastereoselective Roush’s allylboration as key steps. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to enantioselective synthesis bistramide a fragment michael cyclization alkylation, allylation chiral auxiliary enantioselective bistramide a fragment, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On February 11, 2021, Harikrishnan, Lalgudi S.; Park, Peter Kinam; Ruan, Zheming; Wei, Donna D.; O’Malley, Daniel; Wan, Honghe; Purandare, Ashok Vinayak; Fink, Brian E. published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted benzamides as RORγ agonists for the treatment of cancer. And the patent contained the following:

The invention is directed to compounds of the formula I wherein X is N and CR5; R5 is H, CN, halo, etc.; Y is CR6; R6 is H, CN, halo, etc.; R1 is (CH2)0-2-NHCOO-(CRxRy)0-4-R1a,(CH2)0-2-NHCORx-(CRxRy)0-4-R1a, 4-10 membered heterocycle-(CRxRy)0-4-R1a, etc.; each Rx and Ry are independently H and C1-3 alkyl; R1a is H, CF3, OH, etc.; R2 and R3 are independently H, halo and C1-3 alkyl; R4 is C1-6 alkyl, C1-6 alkenyl, C1-6 haloalkyl, etc.; and stereoisomers and pharmaceutically acceptable salt thereof; their preparation and use for the treatment of cancer. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their RORγ agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 1.7 nM. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to benzamide preparation ror gamma agonist treatment cancer, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On January 18, 2017, Jimenez, Jacqueline; Lopez, Mildred; Carranza, Vladimir; Mendoza, Angel; Varela, Jenaro; Sansinenea, Estibaliz; Ortiz, Aurelio published an article.Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one The title of the article was Diastereoselective hydrogenation of α,β-unsaturated but-2-enamides to access the chiral 3-(p-tolyl)butanoic acids. And the article contained the following:

An alternative methodol. for the synthesis of chiral 3-(p-tolyl)butanoic acids is presented. This was accomplished through the diastereoselective hydrogenation reaction of different chiral N-3-(p-tolyl)but-2-enamides, using Pd/C in EtOH, to produce the corresponding chiral N-3-(p-tolyl)butanamides, e.g., I with high chem. yields and moderate diastereomeric ratios. Removal of the chiral auxiliary from N-3-(p-tolyl)butanamides gave the resp. enantiomerically pure acids. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

The Article related to butanoic acid preparation diastereoselective, unsaturated butenamide hydrogenation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 31, 2013, Claridge, Timothy D. W.; Davies, Stephen G.; Kruchinin, Dennis; Odell, Barbara; Roberts, Paul M.; Russell, Angela J.; Thomson, James E.; Toms, Steven M. published an article.Computed Properties of 168297-86-7 The title of the article was Solution phase structures of enantiopure and racemic lithium N-benzyl-N-(α-methylbenzyl)amide in THF: low temperature 6Li and 15N NMR spectroscopic studies. And the article contained the following:

The antipodes of lithium N-benzyl-N-(α-methylbenzyl)amide are highly efficient enantiopure ammonia equivalent for the asym. synthesis of β-amino acid derivatives via conjugate addition to α,β-unsaturated esters. 6Li and 15N NMR spectroscopic studies of doubly labeled 6lithium (S)-15N-benzyl-15N-(α-methylbenzyl)amide in THF at low temperature reveal the presence of lithium amide dimers as the only observable species. Either a monomeric or dimeric lithium amide reactive species can be accommodated within the transition state mnemonic for this class of conjugate addition reaction. This enantiopure lithium amide offers unique opportunities over achiral (e.g., lithium dibenzylamide) and C2-sym. (e.g., lithium bis-N,N-α-methylbenzylamide) counterparts for further mechanistic study owing to the ready distinction of the various dimers formed. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to solution phase structure enantiopure racemate lithium benzylmethylbenzylamide nmr, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 4, 2011, Hoffmann, Matthias; Dahmann, Georg; Fiegen, Dennis; Handschuh, Sandra; Klicic, Jasna; Linz, Guenter; Schaenzle, Gerhard; Schnapp, Andreas; East, Stephen P.; Mazanetz, Michael Philip; Scott, John; Walker, Edward published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted naphthyridines and their use as therapeutic Syk kinase inhibitors. And the patent contained the following:

The invention relates to new substituted naphthyridines of formula I, as well as pharmacol. acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is -O-R3 or -NR3R4, R3 is substituted C1-6-alkyl, R4 is H or C1-6-alkyl, and R2 is H, (un)substituted 5-10-membered aryl, (un)substituted 5-10-membered heteroaryl, etc., as well as pharmaceutical compositions containing these compounds Naphthyridines of formula I are particularly suitable for the treatment of respiratory complaints, allergic diseases, osteoporosis, gastrointestinal diseases, autoimmune diseases, inflammatory diseases and diseases of the peripheral or central nervous system, particularly for the treatment of asthma, allergic rhinitis, rheumatoid arthritis, allergic dermatitis and COPD. Synthetic procedures for preparing I are exemplified. Example compound II, prepared by reacting (R)-4-((R)-1-hydroxyethyl)pyrrolidine-2-one and III, had an IC50 of 0.0131 μM in an Syk kinase luminescence assay. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to preparation naphthyridine syk kinase inhibitor therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem